DigestRedComo funciona
Red
/
Empresas
Co
No verificado

Coya Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

47 Comunicados de prensa

Ver todos los comunicados de prensa
10/02/2026
Web y redes sociales
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
30/01/2026
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Finanzas
Coya Therapeutics Announces $11.1 Million Private Placement
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
20/01/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
08/01/2026
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Análisis de Mercados
Industria
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
05/01/2026
Industria
Psiquiatría
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
23/12/2025
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Industria
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
09/12/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
25/11/2025
Eventos
Web y redes sociales
Salud
Medicina - Varios
Ciencia
Biotecnología
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
12/11/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado de valores
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
04/11/2025
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0